HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
Intra-tumoral heterogeneity presents a major obstacle to cancer therapeutics, including conventional chemotherapy, immunotherapy, and targeted therapies. Stochastic events such as mutations, chromosomal aberrations, and epigenetic dysregulation, as well as micro-environmental selection pressures rel...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/14/3575 |
| _version_ | 1797527470118797312 |
|---|---|
| author | Dimitris Karagiannis Theodoros Rampias |
| author_facet | Dimitris Karagiannis Theodoros Rampias |
| author_sort | Dimitris Karagiannis |
| collection | DOAJ |
| description | Intra-tumoral heterogeneity presents a major obstacle to cancer therapeutics, including conventional chemotherapy, immunotherapy, and targeted therapies. Stochastic events such as mutations, chromosomal aberrations, and epigenetic dysregulation, as well as micro-environmental selection pressures related to nutrient and oxygen availability, immune infiltration, and immunoediting processes can drive immense phenotypic variability in tumor cells. Here, we discuss how histone deacetylase inhibitors, a prominent class of epigenetic drugs, can be leveraged to counter tumor heterogeneity. We examine their effects on cellular processes that contribute to heterogeneity and provide insights on their mechanisms of action that could assist in the development of future therapeutic approaches. |
| first_indexed | 2024-03-10T09:44:13Z |
| format | Article |
| id | doaj.art-94ab347c46fe4261b1cedee1185196bd |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T09:44:13Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-94ab347c46fe4261b1cedee1185196bd2023-11-22T03:25:36ZengMDPI AGCancers2072-66942021-07-011314357510.3390/cancers13143575HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor HeterogeneityDimitris Karagiannis0Theodoros Rampias1Department of Genetics and Development, Columbia University Medical Center, New York, NY 10032, USABiomedical Research Foundation of the Academy of Athens, 11527 Athens, GreeceIntra-tumoral heterogeneity presents a major obstacle to cancer therapeutics, including conventional chemotherapy, immunotherapy, and targeted therapies. Stochastic events such as mutations, chromosomal aberrations, and epigenetic dysregulation, as well as micro-environmental selection pressures related to nutrient and oxygen availability, immune infiltration, and immunoediting processes can drive immense phenotypic variability in tumor cells. Here, we discuss how histone deacetylase inhibitors, a prominent class of epigenetic drugs, can be leveraged to counter tumor heterogeneity. We examine their effects on cellular processes that contribute to heterogeneity and provide insights on their mechanisms of action that could assist in the development of future therapeutic approaches.https://www.mdpi.com/2072-6694/13/14/3575cancertumor heterogeneityepigenetic drugsHDAC inhibitors |
| spellingShingle | Dimitris Karagiannis Theodoros Rampias HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity Cancers cancer tumor heterogeneity epigenetic drugs HDAC inhibitors |
| title | HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity |
| title_full | HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity |
| title_fullStr | HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity |
| title_full_unstemmed | HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity |
| title_short | HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity |
| title_sort | hdac inhibitors dissecting mechanisms of action to counter tumor heterogeneity |
| topic | cancer tumor heterogeneity epigenetic drugs HDAC inhibitors |
| url | https://www.mdpi.com/2072-6694/13/14/3575 |
| work_keys_str_mv | AT dimitriskaragiannis hdacinhibitorsdissectingmechanismsofactiontocountertumorheterogeneity AT theodorosrampias hdacinhibitorsdissectingmechanismsofactiontocountertumorheterogeneity |